Related Experiment Video

Updated: Mar 21, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

4.2K

Targeting CTLA-4, PD-L1 and IDO to modulate immune responses in vitiligo

Reinhart Speeckaert1, Nanja van Geel1

  • 1Department of Dermatology, Ghent University Hospital, Ghent, Belgium.

Experimental Dermatology
|May 20, 2016
PubMed

Insights

Vitiligo treatment may improve by targeting immune checkpoints. Enhancing therapies like CTLA-4 and PD-L1 offers a promising new strategy for vitiligo patients.

Area of Science:

  • Immunodermatology
  • Autoimmune diseases
  • Melanocyte biology

Background:

  • Vitiligo pathophysiology remains debated, but immune-mediated melanocyte destruction is widely accepted.
  • Current vitiligo treatments rely on non-specific immunosuppressants.
  • Melanoma immunotherapy suggests immune checkpoints influence depigmentation.

Purpose of the Study:

  • To propose immune checkpoint enhancement as a novel therapeutic strategy for vitiligo.
  • To explore targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed death ligand-1 (PD-L1), and indoleamine 2,3-dioxygenase (IDO) for vitiligo therapy.

Main Methods:

  • This viewpoint discusses existing research on immune checkpoints and their role in depigmentation.
  • It analyzes the potential of modulating specific immune pathways relevant to vitiligo pathogenesis.
  • The proposed strategy is based on insights from melanoma immunotherapy.

Main Results:

  • Targeting immune checkpoints can potentially reverse natural defense mechanisms that lead to skin depigmentation.
  • Enhancing immune checkpoints like CTLA-4, PD-L1, and IDO may offer a viable therapeutic avenue.

Conclusions:

  • Immune checkpoint enhancement represents a promising long-term therapeutic option for vitiligo.
  • Further research into these specific targets could lead to more effective vitiligo treatments.
Keywords:
cytotoxic T-lymphocyte-associated protein 4indoleamine 2,3-dioxygenaseperipheral toleranceprogrammed death ligand-1vitiligo

More Related Videos

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

9.6K
In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction08:02

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

6.0K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.1K